...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International immunopharmacology >Therapeutic advances in the treatment of SLE
【24h】

Therapeutic advances in the treatment of SLE

机译：治疗SLE治疗的治疗进展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In recent years, the research on the pathogenesis of systemic lupus erythematosus (SLE) has been deepened, from the level of histopathology to the cellular and molecular biology, thus promoting the progress of SLE drug therapeutics. In March 2011, the United States Food and Drug Administration (FDA) approved the humanized monoclonal antibody, Belimumab for the treatment of SLE and put an end to the dilemma of no new drug available to SLE for more than half a century. On the other hand, the continuous evidence-based medical information has enabled rheumatologists to have a more comprehensive and depth understanding of the application of SLE traditional therapies, further improve the treatment strategy of SLE and put forward higher requirements for treatment goals. At the same time, advances in therapies have significantly improved survival rate of the patients, and the importance of long-term complications such as early-onset atherosclerosis and cardiovascular events has become increasingly apparent as a new challenge. In view of the hot issues of SLE clinical treatment, this paper introduces the research progress in recent years.
机译：近年来，从细胞和分子生物学的组织病理学水平深化了对系统性红斑狼疮（SLE）的发病机制的研究，从而促进了SLE药物治疗的进展。 2011年3月，美国食品和药物管理局（FDA）批准了人源化的单克隆抗体，Belimumab用于治疗SLE，并结束No No Ne Mave的新药物的困境。另一方面，基于持续的循证医学信息使风湿病学家能够更全面和深入了解SLE传统疗法的应用，进一步改善了SLE的治疗策略，并提出了对治疗目标的更高要求。同时，疗法的进展显着提高了患者的存活率，长期并发症如早期并发症和心血管事件的重要性变得越来越明显成为一种新的挑战。鉴于SLE临床治疗的热门问题，本文介绍了近年来的研究进展。

著录项

  • 来源
    《International immunopharmacology》 |2019年第2019期|共6页
  • 作者

    Mohamed Ali; Chen Yongjian; Wu Haijing; Liao Jieyue; Cheng Bo; Lu Qianjin;

  • 作者单位

    Cent S Univ Dept Dermatol Hunan Key Lab Med Epigen Xiangya Hosp 2 139 Middle Renmin Rd;

    Cent S Univ Dept Dermatol Hunan Key Lab Med Epigen Xiangya Hosp 2 139 Middle Renmin Rd;

    Cent S Univ Dept Dermatol Hunan Key Lab Med Epigen Xiangya Hosp 2 139 Middle Renmin Rd;

    Cent S Univ Dept Dermatol Hunan Key Lab Med Epigen Xiangya Hosp 2 139 Middle Renmin Rd;

    Fujian Med Univ Affiliated Hosp 1 Dept Dermatol Fuzhou Fujian Peoples R China;

    Cent S Univ Dept Dermatol Hunan Key Lab Med Epigen Xiangya Hosp 2 139 Middle Renmin Rd;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

    SLE; Monoclonal antibody; IL-2; Lupus nephritis;

    机译：SLE;单克隆抗体;IL-2;狼疮肾炎;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号